Abstracts tagged "WOMAC"

Abstract Number: 2626 • ACR Convergence 2025
Lorecivivint Delayed Time to Pain and Function Worsening Compared to Placebo: Evaluation of Knee OA Symptom Progression Outcomes in a Phase 3 Trial (OA-07)
Yusuf Yazici¹ and Christopher Swearingen², ¹NYU Grossman School of Medicine, La Jolla, CA, ²Biosplice Therapeutics, Inc, San Diego, CA
Background/Purpose: Increased pain and decreased function are hallmarks of knee OA progression. Lorecivivint (LOR), an intra-articular CLK/DYRK inhibitor thought to modulate inflammatory and Wnt pathways,…
Abstract Number: 2103 • ACR Convergence 2025
PCRX-201 High-Capacity Adenovirus Serotype 5 Gene Therapy Demonstrates Sustained Clinical Efficacy and Safety in Patients With Knee Osteoarthritis
Stanley Cohen¹, Philip Conaghan², Marc C. Hochberg³, Alan Kivitz⁴, MiJeong Kim⁵, Nino Joy⁶, Shoshanna Jiang⁶, Mary DiGiorgi⁷, Jonathan Slonin⁶ and Derek Slonin⁶, ¹Metroplex Clinical Research Center, dallas, TX, ²University of Leeds, Leeds, United Kingdom, ³Marc C. Hochberg University of Maryland School of Medicine, Baltimore, MD, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵Pacira BioSciences, Inc., Brisbane, ⁶Pacira BioSciences, Inc., Brisbane, CA, ⁷Pacira BioSciences, Inc, Brisbane, CA
Background/Purpose: Knee OA is a common disease affecting ~15 million people in the United States. There is an urgent unmet need for additional OA treatments…
Abstract Number: 2083 • ACR Convergence 2025
Evaluation of a Parent-Trial as a Run-In Period: Efficacy and Safety of Repeat Injections of Lorecivivint over Three Years
Christopher Swearingen¹ and Yusuf Yazici², ¹Biosplice Therapeutics, Inc, San Diego, CA, ²NYU Grossman School of Medicine, La Jolla, CA
Background/Purpose: Lorecivivint (LOR) is an intra-articular CLK/DYRK inhibitor in clinical development for the treatment of knee OA. A Phase 3 Trial, OA-11 (NCT03928184), assessed clinical…
Abstract Number: 1222 • ACR Convergence 2025
Efficacy of Fasinumab, An Anti-Nerve Growth Factor Monoclonal Antibody, in Managing Chronic Musculoskeletal Pain: A Systematic Review and Meta-Analysis
Ahmed Abouelella¹, Mohammad Alhasan², Ahmed Hamoudah³, Ayman Ibrahim⁴, Ola O.A. Abuzied⁵, Mansoor Al-Tamimi⁶ and Muhammed Elhadi⁷, ¹Faculty of Medicine, Benha University, Benha, Al Qalyubiyah, Egypt, ²Health Education England Internal Medicine Training ( Cambridge), Cambridge, United Kingdom, ³Libyan International University, Sarasota, FL, ⁴University of Gezira, Medina, Saudi Arabia, ⁵University of Khartoum, Khartoum, Sudan, ⁶Faculty of Medicine, Cairo University, Cairo, Egypt, ⁷University of Tripoli, Huston, TX
Background/Purpose: Chronic musculoskeletal pain can be a significant source of disability and poor quality of life in adults. Many patients do not achieve adequate relief…
Abstract Number: 1127 • ACR Convergence 2025
The Pathogenetic Role of Calcium Pyrophosphate and Basic Calcium Phosphate Crystals in Osteoarthritis: Associations with Synovial Fluid Cytokines and Clinical Indices
Francesca Oliviero¹, Chiara Baggio², Amelia Damasco², Federico Zorzi³, Mariagrazia Lorenzin², Giacomo Cozzi² and Roberta Ramonda⁴, ¹Rheumatology Unit, Department od Medicine - DIMED, University of Padova, Padova, Veneto, Italy, ²Rheumatology Unit, Department of Medicine - DIMED, University of Padova, Padova, Veneto, Italy, ³Center for Analysis and Certification Services (CEASC), University of Padova, Padova, Veneto, Italy, ⁴Rheumatology Unit-DIMED-University of Padova ITALY, Padova, Padua, Italy
Background/Purpose: Calcium pyrophosphate (CPP) and basic calcium phosphate (BCP) crystals are frequent features of synovial fluid (SF) in patients with osteoarthritis (OA). Although these crystals…
Abstract Number: 0852 • ACR Convergence 2025
LEVI-04 Significantly Reduces Bone Marrow Lesions and Symptoms in Knee Osteoarthritis: Results from a Phase II RCT
Simon Westbrook¹, Ali Guermazi² and Philip Conaghan³, ¹Levicept Ltd, Sandwich, United Kingdom, ²Boston University, West Roxbury, MA, ³University of Leeds, Leeds, United Kingdom
Background/Purpose: Bone marrow lesions (BMLs), detectable on MRI as areas of ill-defined high signal intensity on fluid-sensitive sequences, are a common feature of osteoarthritis (OA),…
Abstract Number: 0331 • ACR Convergence 2025
Safety and Efficacy of Colchicine in Osteoarthritis: A Systematic Review and Meta-Analysis of 6,965 Patients
Mohamed Abdelsalam¹, Bassant Elaraby Elsayed Badwy², Menat Alla Ayman Ali Mahdy², Maryam Lasheen³, Hadeer Hafez⁴, Omar Sameh Nabil El Sedafy¹ and Mohamed Reda Awad⁵, ¹Misr University For Science and Technology, ⁶ october, Al Jizah, Egypt, ²Misr University For Science and Technology, Nasr City, Al Qahirah, Egypt, ³Misr University For Science and Technology, Helwan, Al Qahirah, Egypt, ⁴⁶th October University, ⁶ october, Al Jizah, Egypt, ⁵Al Azhar University, Cairo, Egypt, Giza, Al Jizah, Egypt

Background/Purpose: Osteoarthritis (OA) is the most common joint disease, that leads to significant pain and affects quality of life, particularly in older adults. Current treatments…
Abstract Number: L08 • ACR Convergence 2024
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-ranging and Parallel-group Study to Evaluate the Safety and Efficacy of XG005 in Subjects with Painful Osteoarthritis of the Knee
Limin Ren¹, Wenjie Zheng², Zhenpeng Guan³, Yang Zhang⁴, Zeyu Huang⁵, Tong Li⁶, Yuwei Peng⁷, Qiuli Wu⁸, Wei Gou⁹, Wei Zhao¹⁰, Pengyan Qiao¹¹, Xiaoli Pan¹² and Guang-Liang Jiang¹³, ¹Peking University, People’s Hospital, Rheumatology and Immunology Department, Beijing, China, ²Yantai Yuhuangding Hospital of Qingdao University, Department of Orthopedics, Yantai, China, ³Peking University, Shougang Hospital, Department of Orthopedics, Beijing, China, ⁴Division of Orthopaedic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, ⁵West China Hospital of Sichuan University, Department of Orthopedics, Chengdu, China, ⁶Xiangya Hospital of Central South University, Rheumatology and Immunology Department, Changsha, China, ⁷PingXiang People’s Hospital, Rheumatology and Immunology Department, Pingxiang, China, ⁸Tianjin Medical University General Hospital, Department of Orthopedics, Tianjin, China, ⁹Hebei Petrochina Central Hospital, Rheumatology and Immunology Department, Langfang, China, ¹⁰Central Hospital Affiliated to Shenyang Medical College, Department of Orthopedics, Shenyang, China, ¹¹Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Rheumatology and Immunology Department, Taiyuan, China, ¹²Affiliated Hospital of Zunyi Medical University, Rheumatology and Immunology Department, Zunyi, China, ¹³Xgene Pharmaceutical, Lexington, MA
Background/Purpose: Osteoarthritis (OA) affects 595 million people globally; cases are projected to increase 49-95% for various joints by 2050 as populations age (GBD 2023). OA…
Abstract Number: 1196 • ACR Convergence 2024
Relation of Different Types of Antidepressants Use to Pain Severity and Measures of Pain Sensitization in Kneeosteoarthritis
Zhiqiang Wang¹, Brooke Mcginley², mike LaValley³, Laura Frey-Law⁴, Beth Lewis⁵, Michael Nevitt⁶, Margaret Clancy⁷, Changhai Ding⁸ and Tuhina Neogi⁷, and MOST investigators, ¹Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, Guangdong, China (People's Republic), ²Boston University, Boston, MA, ³Boston University School of Public Health, Arlington, MA, ⁴Carver College of Medicine, Iowa City, IA, ⁵School of Kinesiology , Kinesiology College of Education and Human Development, Twin Cities, Minneapolis, MN, ⁶UCSF, Orinda, CA, ⁷Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁸Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China (People's Republic)
Background/Purpose: The pain experience in osteoarthritis (OA) is multifactorial and includes both somatosensory and affective components. The affective component can be related to depression, a…
Abstract Number: 1199 • ACR Convergence 2024
Diclofenac Sodium 1% Gel Improves Physical Function in the Performance of Important Activities of Daily Living in Patients with Hand or Knee Osteoarthritis
Karin Nicholson, Edwin Sanchez, Nadine Maybaum and Richard Petruschke, Haleon, Warren, NJ
Background/Purpose: Osteoarthritis (OA) is the most common form of arthritis, with hand and knee being among the most afflicted joints. Symptoms of OA include joint…
Abstract Number: 1204 • ACR Convergence 2024
Immunobased Profiling of Knee Osteoarthritis Patients to Predict Response to Regenerative Treatment with Autologous Blood-derivative Platelet-Rich Plasma Injection
Antonio Tonutti¹, Valentina Granata², Veronica Marrella², Cristina Sobacchi², Rita Ragusa³, Marzia Monferini³, Cristiano sconza³, Nicola rani⁴, Berardo Di Matteo⁵, Carlo Selmi⁶ and Angela Ceribelli⁵, ¹Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Rozzano, Italy, ²Humanitas Research Hospital and Institute for Genetic and Biomedical Research, Rozzano, Italy, ³Humanitas Research Hospital, Rozzano, Italy, ⁴Rizzoli Orthopaedic Institute, Bologna, Italy, ⁵Humanitas University and Humanitas Research Hospital, Rozzano, Italy, ⁶Department of Biomedical Sciences, Humanitas University, Rozzano, Italy
Background/Purpose: Osteoarthritis (OA) is a degenerative musculoskeletal disease causing chronic disability and elevated social costs worldwide. Its multifactorial origin contributes to different OA phenotypes and…
Abstract Number: 0792 • ACR Convergence 2024
Radiographic and Pain Outcomes from a Phase 3 Trial (OA-07) Evaluating the Efficacy and Safety of Repeat Lorecivivint Injections over 3 Years in Subjects with Knee OA
Yusuf Yazici¹, Jeyanesh Tambiah², Christopher Swearingen³ and Timothy McAlindon⁴, ¹NYU Grossman School of Medicine, La Jolla, CA, ²Biosplice Therapeutics Inc., San Diego, CA, ³Biosplice Therapeutics, Inc, San Diego, CA, ⁴University of Massachusets, Worchester, MA
Background/Purpose: Knee OA has unmet need for safe and efficacious symptom and disease-modifying treatments. Lorecivivint (LOR), an intra-articular (IA) CLK/DYRK inhibitor thought to modulate inflammatory…
Abstract Number: 1184 • ACR Convergence 2024
Sustained Clinical Effects After a Single Intra-articular Injection of PCRX-201 for Moderate-to-Severe Osteoarthritis of the Knee
Stanley Cohen¹, Philip G Conaghan², Marc Hochberg³, Alan Kivitz⁴, Nino Joy⁵, Derek Jackson⁵, Masato Nakazawa⁵, Mary DiGiorgi⁵ and Jonathan Slonin⁵, ¹Metroplex Clinical Research Center, dallas, TX, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ³University of Maryland School of Medicine, Baltimore, MD, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵Pacira BioSciences, Inc., Tampa, FL
Background/Purpose: Osteoarthritis of the knee (OAK) is a common and severe disease. Current treatments provide temporary pain relief, demonstrating unmet need. PCRX-201 is a high…
Abstract Number: 1187 • ACR Convergence 2024
Association of Depressive Symptoms and Multiple Joint Osteoarthritis with Pain Outcomes in the WE-CAN Trial
Natalie Allcott¹, Stephen Messier², Shannon Mihalko², Jeffrey Katz³, Paul DeVita⁴, David Hunter⁵, Sara Quandt⁶, Carolina Alvarez⁷, Leigh Callahan⁸ and Amanda Nelson¹, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Wake Forest University, Winston Salem, NC, ³Brigham and Women's Hospital, Brookline, MA, ⁴Eastern Carolina University, Greenville, ⁵Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia, ⁶Wake Forest University, Winston-Salem, ⁷University of North Carolina at Chapel Hill, Miami, FL, ⁸University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC
Background/Purpose: The Weight-loss and Exercise for Communities with Arthritis in North Carolina (WE-CAN) trial was a community-based, pragmatic randomized clinical trial in men and women…
Abstract Number: L04 • ACR Convergence 2023
EP-104IAR (Extended-Release Fluticasone Propionate for Injectable Suspension): Topline and Key Secondary Results from a Phase 2 Randomized, Double-blind, Vehicle-Controlled Trial in Subjects with Knee Osteoarthritis
James Helliwell¹, Amanda Malone¹, Mark Kowalski², Asger Reinstrup Bihlet³, Claire Miller⁴, Alejandro Castillo Mondragon⁵, Yanqi Li⁶, Christine Dobek⁷, Vik Peck¹, Mike Wilmink⁸ and Lee Simon⁹, ¹Eupraxia Pharmaceuticals, Victoria, BC, Canada, ²Eupraxia Pharmaceuticals, Winchester, VA, ³NBCD A/S, Soeborg, Denmark, ⁴NBCD A/S, Copenhagen, Denmark, ⁵NBCD, Copenhagen, Denmark, ⁶NBCD A/S, Soborg, Denmark, ⁷Eupraxia Pharmaceuticals, Edmonton, AB, Canada, ⁸OrthoArizona, Phoenix, AZ, ⁹SDG LLC, Cambridge, MA
Background/Purpose: EP-104IAR is being developed to treat OA symptoms. Previous results from non-clinical studies evaluating local joint safety in beagle dogs, in contrast to other…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].